At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Spironolactone/Vitamin Edrug
Likely dose
Spironolactone/Vitamin E 25 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study
In Brief
A Phase 2 clinical trial evaluating Spironolactone/Vitamin E for Fatty Liver and Steatohepatitis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The primary aim of the study is the effect of spironolactone and vitamin E versus vitamin E on serum levels of adipokines 52 weeks post-treatment.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFatty Liver, Steatohepatitis
CountriesGreece
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJan 2010
First PostedJun 2010
Primary CompletionNov 2010
Study CompletionDec 2011
TodayJul 2026
First PostedJun 22, 2010
Enrollment StartJan 1, 2010
Primary CompletionNov 1, 2010
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 16.0 years ago
Interventions
Spironolactone/Vitamin Edrug
Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks